Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Murphey, L.
Right arrow Articles by Brown, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Murphey, L.
Right arrow Articles by Brown, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Contribution of bradykinin to the cardioprotective effects of ACE inhibitors

L. Murphey1,1, D. Vaughan2,3 and N. Brown1

a Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
b Division of Cardiovascular Medicine, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
c Veterans Affairs Medical Center, Nashville, Tennessee, USA

1 Laine J. Murphey, MD, PhD, 556A Robinson Research Building, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA

Abstract

Bradykinin, through its B2 receptor, stimulates endothelial release of a number of vasodilators, such as nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). Angiotensin-converting enzyme (ACE) inhibitors enhance the effects of local bradykinin by decreasing its degradation and by increasing B2 receptor sensitivity. Clinical and experimental studies demonstrate that blockade of the B2 receptor attenuates the antihypertensive, antihypertrophic, and antiatherosclerotic effects of ACE inhibitors. Thus, the evidence strongly supports a role for bradykinin in mediating the cardiovascular benefits of ACE inhibitors.

Key Words: ACE inhibitors • ramipril • bradykinin • endothelial dysfunction • kallikrein-kinin system • renin-angiotensin system


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
K. K. Koh, M. J. Quon, Y. Lee, S. H. Han, J. Y. Ahn, W.-J. Chung, J.-a Kim, and E. K. Shin
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients
Eur. Heart J., June 2, 2007; 28(12): 1440 - 1447.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.